Oncology Precision Medicine Market – A Global and Regional Analysis: Focus on Ecosystem and Application – Analysis and Forecast, 2020-2031

Table of Contents

1 Markets 1.1 Industry Outlook 1.1.1 Introduction 1.2 Evolution of Precision Medicine for Cancer Management and Treatment 1.3 Applications of Precision Medicine in Oncology 1.3.1 Identifying Genetic Mutations and Risks of Cancer Through Precision Diagnostics 1.3.2 Promising Technological Developments Supporting Precision Oncology 1.3.2.1 Low-Throughput Genomic Sequencing to High-Throughput Genomic Sequencing 1.3.2.2 Multicell Hybrid Detection to Single-Cell Precision Detection 1.3.2.3 Advancing Applications of ctDNA Detection Technology 1.3.2.4 CRISPR/Cas Technology 1.4 Impact of COVID-19 Pandemic on Global Oncology Precision Medicine Market 1.4.1 Disruption of Oncology Precision Medicine Due to COVID-19 1.4.2 COVID-19 Affecting Supply Chain of Oncology Precision Medicine-Based Therapies 1.4.3 Interruption in Research and Clinical Development and Commercial Operation 1.4.3.1 Research and Clinical Development 1.4.4 Commercial Operation and Access 1.4.5 Navigating Crisis Recovery and Looking to the Future 1.5 Market Dynamics 1.5.1 Impact Analysis 1.5.2 Market Drivers 1.5.2.1 Increasing Incidence of Cancer Globally 1.5.2.2 Decreasing Trial and Error-Based Drug Prescription Through Pharmacogenomics 1.5.2.3 Increasing Usage of Predictive Biomarker for Cancer Diagnostics 1.5.2.4 Rapid Technological Advancements related to Oncology Precision Medicine 1.5.2.5 Decreasing Cost and Increase in the Output of Genomic Sequencing 1.5.3 Restraints 1.5.3.1 Large Scale Data Integration, Analysis, and Establishment of Secure Data Libraries 1.5.3.2 Inadequate Reimbursement Scenario for Precision Medicine 1.5.3.3 Barriers in the Advancement of Precision Medicine 1.5.3.3.1 Regulatory Barriers 1.5.3.4 Lack of Expertise, Education, and Awareness for Precision Medicine Implementation 1.6 Market Opportunities 1.6.1 Unprecedented Improvements in Disease Modelling via In-Silico, In-Vitro, and In-Vivo Methods 1.6.2 Expansion into the Emerging Markets 1.6.3 Rising Number of Initiatives for Precision Oncology Research 1.7 Competitive Landscape 1.7.1 Acquisitions 1.7.2 Synergistic Activities 1.7.3 Product Launches, Approvals, and Upgradations 1.7.4 Business Expansion 1.7.5 Market Share Analysis 1.7.6 Growth Share Analysis 1.7.6.1 Growth Share Analysis (by Application) 1.7.6.2 Growth Share Analysis (by Ecosystem) 1.8 Industry Insights 1.8.1 Legal and Regulatory Framework and Requirements 1.8.2 North America 1.8.2.1 Regulatory Requirements in U.S. 1.8.3 Europe 1.8.3.1 U.K. 1.8.3.1.1 Regulatory Requirements in U.K. 1.8.3.1.1.1 The Cancer Plan 1.8.4 Asia-Pacific 1.9 Legal Requirements and Framework by MHLW 1.1 Legal Requirement and Framework by NMPA 1.11 Patent Analysis 1.11.1 Patent Filing Trend 1.11.1.1 Patent Analysis (by Region) 1.11.1.2 Patent Analysis (by Country) 2 Global Oncology Precision Medicine Market, by Ecosystem, $ Million, 2020-2031 2.1 Overview 2.1.1 Precision Therapeutics 2.1.1.1 Clinical Trials 2.1.1.2 Biomarker Testing 2.1.1.3 Drug Discovery and Research 2.1.1.4 Gene Therapy 2.1.1.5 Cell Therapy 2.1.2 Applied Sciences 2.1.2.1 Genomics 2.1.2.1.1 Polymerase Chain Reaction (PCR) 2.1.2.1.2 Precision Medicine Next-Generation Sequencing 2.1.2.1.3 Genome Editing 2.1.2.1.4 Other Technologies 2.1.2.2 Pharmacogenomics 2.1.2.3 Other Applied Sciences 2.1.3 Digital Health and Information Technology 2.1.3.1 Clinical Decision Support System (CDSS) 2.1.3.2 Big Data Analytics 2.1.3.3 IT Infrastructure 2.1.3.4 Genomics Informatics 2.1.3.5 In-Silico Informatics 2.1.3.6 Mobile Health 2.1.4 Precision Diagnostics 2.1.4.1 Molecular Diagnostics (MDx) 2.1.4.2 Medical Imaging 3 Global Oncology Precision Medicine Market, by Application, $ Million, 2020-2031 3.1 Overview 3.1.1 Solid Tumor 3.1.1.1 Breast Cancer 3.1.1.2 Lung Cancer 3.1.1.3 Colorectal Cancer 3.1.1.4 Prostate Cancer 3.1.1.5 Cervical Cancer 3.1.1.6 Other Cancer 3.1.2 Hematological Malignancies (HMs) 3.1.2.1 Leukemia 3.1.2.2 Lymphoma 3.1.2.3 Myeloma or Multiple Myeloma (MM) 3.1.2.4 Other Hematological Malignancies 4 Global Oncology Precision Medicine Market, by Regions, $ Million, 2020-2031 4.1 Overview 4.2 North America 4.2.1 Key Competitors (by Ecosystem) 4.2.2 North America Oncology Precision Medicine Market (by Application) 4.2.3 Key Trends in the North America Oncology Precision Medicine Market 4.2.4 U.S. 4.2.5 Canada 4.3 Europe 4.3.1 Key Competitors (by Ecosystem) 4.3.2 Europe Oncology Precision Medicine Market (by Application) 4.3.3 Key Trends of Europe Oncology Precision Medicine Market 4.3.4 Germany 4.3.5 U.K. 4.3.6 France 4.3.7 Italy 4.3.8 Spain 4.3.9 Rest-of-Europe 4.4 Asia-Pacific 4.4.1 Key Competitors (by Ecosystem) 4.4.2 Asia-Pacific Oncology Precision Medicine Market (by Application) 4.4.3 Key Trends in the Asia-Pacific Oncology Precision Medicine Market 4.4.4 China 4.4.5 India 4.4.6 Japan 4.4.7 Australia 4.4.8 South Korea 4.4.9 Rest-of-Asia-Pacific 4.5 Latin America (LATAM) 4.5.1 Key Competitors (by Ecosystem) 4.5.2 Latin America Oncology Precision Medicine Market (by Application) 4.5.3 Key Trends in the Latin America Oncology Precision Medicine Market 4.5.4 Brazil 4.5.5 Mexico 4.5.6 Rest-of-Latin America 4.6 Rest-of-the-World (RoW) 4.6.1 Key Competitors (by Ecosystem) 4.6.2 Rest-of-the-World Oncology Precision Medicine Market (by Application) 4.6.3 Key Trends in the Rest-of-the-World Oncology Precision Medicine Market 5 Markets - Competitive Benchmarking & Company Profiles 5.1 Overview 5.2 Agilent Technologies, Inc. 5.2.1 Company Overview 5.2.2 Role of Agilent Technologies, Inc. in the Global Oncology Precision Medicine Market 5.2.3 Key Competitors of the Company 5.2.4 Financials 5.2.5 Key Insights About Financial of the Company 5.2.6 Corporate Strategies 5.2.6.1 Mergers and Acquisitions 5.2.6.2 Synergistic Activities 5.2.6.3 Business Expansion and Funding 5.2.6.4 Product Launches and Upgradation 5.2.7 SWOT Analysis 5.3 Bio-Rad Laboratories, Inc. 5.3.1 Company Overview 5.3.2 Role of Bio-Rad Laboratories, Inc. in the Global Oncology Precision Medicine Market 5.3.3 Key Competitors of the Company 5.3.4 Financials 5.3.5 Key Insights About Financial Health of the Company 5.3.6 Corporate Strategies 5.3.6.1 Product Launches and upgradation 5.3.7 SWOT Analysis 5.4 Illumina, Inc. 5.4.1 Company Overview 5.4.2 Role of Illumina, Inc. in the Global Oncology Precision Medicine Market 5.4.3 Key Competitors of the Company 5.4.4 Financials 5.4.5 Key Insights About Financial Health of the Company 5.4.6 Corporate Strategies 5.4.6.1 Mergers and Acquisition 5.4.6.2 Synergistic Activities 5.4.6.3 Business Expansion and Funding 5.4.6.4 Product Launches and Upgradation 5.4.7 SWOT Analysis 5.5 Pacific Biosciences of California, Inc. 5.5.1 Company Overview 5.5.2 Role of Pacific Biosciences of California, Inc. in the Global Oncology Precision Medicine Market 5.5.3 Key Competitors of the Company 5.5.4 Financials 5.5.5 Key Insights About Financial Health of the Company 5.5.6 Corporate Strategies 5.5.6.1 Mergers and Acquisition 5.5.6.2 Synergistic Activities 5.5.6.3 Product Launches and Upgradation 5.5.7 SWOT Analysis 5.6 PerkinElmer Inc. 5.6.1 Company Overview 5.6.2 Role of PerkinElmer Inc. in the Global Oncology Precision Medicine Market 5.6.3 Key Competitors of the Company 5.6.4 Financials 5.6.5 Key Insights About Financial Health of the Company 5.6.6 Corporate Strategies 5.6.6.1 Mergers and Acquisition: 5.6.6.2 Synergistic Activities 5.6.6.3 Business Expansion and Funding 5.6.6.4 Product Launches and Upgradation 5.6.7 SWOT Analysis 5.7 QIAGEN 5.7.1 Company Overview 5.7.2 Role of QIAGEN in the Global Oncology Precision Medicine Market 5.7.3 Key Competitors of the Company 5.7.4 Financials 5.7.5 Key Insights About Financial Health of the Company 5.7.6 Corporate Strategies 5.7.6.1 Mergers and Acquisition 5.7.6.2 Synergistic Activities 5.7.6.3 Business Expansion and Funding 5.7.6.4 Product Launches and Upgradation 5.7.7 SWOT Analysis 5.8 Thermo Fisher Scientific Inc. 5.8.1 Company Overview 5.8.2 Role of Thermo Fisher Scientific Inc. in the Global Oncology Precision Medicine Market 5.8.3 Key Competitors of the Company 5.8.4 Financials 5.8.5 Key Insights About Financial Health of the Company 5.8.6 Corporate Strategies 5.8.6.1 Mergers and Acquisition 5.8.6.2 Synergistic Activities 5.8.6.3 Business Expansion and Funding 5.8.6.4 Product Launches and Upgradation 5.8.7 SWOT Analysis 5.9 BGI Group 5.9.1 Company Overview 5.9.2 Role of BGI Group in the Global Oncology Precision Medicine Market 5.9.3 Key Competitors of the Company 5.9.4 Corporate Strategies 5.9.4.1 Mergers and Acquisitions 5.9.4.2 Synergistic Activities 5.9.4.3 Business Expansion and Funding 5.9.4.4 Product Launches and Upgradation 5.9.5 SWOT Analysis 5.1 ASURAGEN, INC. 5.10.1 Company Overview 5.10.2 Role of ASURAGEN, INC. in Global Oncology Precision Medicine Market 5.10.3 Key Competitors of the Company 5.10.4 Corporate Strategies 5.10.4.1 Synergistic Activities 5.10.4.2 Business Expansion and Funding 5.10.4.3 Product Launches and Upgradation 5.10.5 SWOT Analysis 5.11 Almac Group Ltd. 5.11.1 Company Overview 5.11.2 Role of Almac Group Ltd. in Global Oncology Precision Medicine Market 5.11.3 Key Competitors of the Company 5.11.4 Corporate Strategies 5.11.4.1 Mergers and Acquisitions 5.11.4.2 Synergistic Activities 5.11.4.3 Business Expansion and Funding 5.11.4.4 Product Launches and Upgradation 5.11.5 SWOT Analysis 5.12 MDxHealth 5.12.1 Company Overview 5.12.2 Role of MDxHealth in the Global Oncology Precision Medicine Market 5.12.3 Key Competitors of the Company 5.12.4 Financials 5.12.5 Key Insights About Financial Health of the Company 5.12.6 Corporate Strategies 5.12.6.1 Mergers and Acquisitions 5.12.6.2 Synergistic Activities 5.12.6.3 Business Expansion and Funding 5.12.6.4 Product Launches and Upgradation 5.12.7 SWOT Analysis 5.13 Abbott Laboratories 5.13.1 Company Overview 5.13.2 Role of Abbott Laboratories in the Global Oncology Precision Medicine Market 5.13.3 Key Competitors of the Company 5.13.4 Financials 5.13.5 Corporate Strategies 5.13.5.1 Mergers and Acquisitions 5.13.5.2 Synergistic Activities 5.13.5.3 Business Expansion and Funding 5.13.5.4 Product launches and Upgradation 5.13.6 SWOT Analysis 5.14 F. Hoffmann-La Roche Ltd 5.14.1 Company Overview 5.14.2 Role of F. Hoffman-LA Roche Ltd in the Global Oncology Precision Medicine Market 5.14.3 Key Competitors of the Company 5.14.4 Financials 5.14.5 Corporate Strategies 5.14.5.1 Mergers and Acquisitions 5.14.5.2 Synergistic Activities 5.14.5.3 Business Expansion and Funding 5.14.5.4 Product Launches and Upgradation 5.14.6 SWOT Analysis 5.15 Gilead Sciences, Inc. 5.15.1 Company Overview 5.15.2 Role of Gilead Sciences, Inc. in the Global Oncology Precision Medicine Market 5.15.3 Key Competitors of the Company 5.15.4 Financials 5.15.5 Corporate Strategies 5.15.5.1 Mergers and Acquisitions 5.15.5.2 Synergistic Activities 5.15.5.3 Business Expansion and Funding 5.15.5.4 Product Launches and Upgradation 5.15.6 SWOT Analysis 5.16 Myriad Genetics, Inc 5.16.1 Company Overview 5.16.2 Role of Myriad Genetics, Inc. in the Global Oncology Precision Medicine Market 5.16.3 Key Competitors of the Company 5.16.4 Financials 5.16.5 Key Insights About Financial Health of the Company 5.16.6 Corporate Strategies 5.16.6.1 Mergers and Acquisitions 5.16.6.2 Synergistic Activities 5.16.6.3 Business Expansion and Funding 5.16.6.4 Product Launches and Upgradation 5.16.7 SWOT Analysis 5.17 OPKO Health, Inc. 5.17.1 Company Overview 5.17.2 Role of OPKO Health, Inc. in the Global Oncology Precision Medicine Market 5.17.3 Key Competitors of the Company 5.17.4 Financials 5.17.5 Corporate Strategies 5.17.5.1 Mergers and Acquisitions 5.17.5.2 Synergistic Activities 5.17.5.3 Business Expansion and Funding 5.17.5.4 Product Launches and Upgradation 5.17.6 SWOT Analysis 5.18 Quest Diagnostics Incorporated 5.18.1 Company Overview 5.18.2 Role of Quest Diagnostics Incorporated in the Global Oncology Precision Medicine Market 5.18.3 Key Competitors of the Company 5.18.4 Financials 5.18.5 Corporate Strategies 5.18.5.1 Mergers and Acquisitions 5.18.5.2 Synergistics Activities 5.18.5.3 Business Expansion and Funding 5.18.5.4 Product Launches and Upgradation 5.18.6 SWOT Analysis 5.19 Novartis AG 5.19.1 Company Overview 5.19.2 Role of Novartis AG in the Global Oncology Precision Medicine Market 5.19.3 Key Competitors of the Company 5.19.4 Financials 5.19.5 Corporate Strategies 5.19.5.1 Synergistic Activities 5.19.5.2 Business Expansion and Funding 5.19.5.3 Product Launches and Upgradation 5.19.6 SWOT Analysis 5.2 Emerging Companies 5.20.1 Prelude Therapeutics 5.20.1.1 Company Overview 5.20.2 AceTech 5.20.2.1 Company Overview 5.20.3 Flatiron 5.20.3.1 Company Overview 5.20.4 Biosplice Therapeutics, Inc. 5.20.4.1 Company Overview List of Figures Figure 1: Overall Deaths Due to Key Cancer Causes, Million, 2012-2019 Figure 2: Global Oncology Precision Medicine Market, $Million, 2020-2031 Figure 3: Global Oncology Precision Medicine Market, Market Dynamics Figure 4: Share of Key Developments and Strategies, January 2018-January 2022 Figure 5: Global Oncology Precision Medicine Market (by Ecosystem), $Million, 2020 Vs. 2031 Figure 6: Global Oncology Precision Medicine Market (by Application), $Million, 2020 Vs. 2031 Figure 7: Global Oncology Precision Medicine Market (by Region), 2020 Vs. 2031 Figure 8: Global Oncology Precision Medicine Market Research Methodology Figure 9: Share of Total Number of Companies Profiled Figure 10: Global Oncology Precision Medicine Market: Segmentation Figure 11: Global Oncology Precision Medicine Market, $Million, 2020-2031 Figure 12: Evolution of Precision Medicine Technology Figure 13: Molecular Diagnostics in Oncology Figure 14: Number of Cancer Cases Diagnosed in the Netherlands (January 3, 2020 - April 5 2020) Figure 15: Pre-COVID-19 and Post-COVID-19 Scenario of Global Oncology Precision Medicine Market, 2017-2025 Figure 16: Areas of Disruption in Clinical Development Figure 17: Measure to Navigate Crisis Recovery Figure 18: Global Oncology Precision Medicine Market - Market Dynamics Figure 19: Estimated Tracheal, Bronchus and Lung Cancer Incidences (Region-Wise), 2020 and 2030(E) Figure 20: Estimated Cancer Mortality (Region-Wise), 2020 Figure 21: Decreasing Cost and Increasing Output of Genome Sequencing, 2009-2025 Figure 22: Share of Key Developments and Strategies, January 2018-January 2022 Figure 23: Share of Acquisitions (by Company), January 2018-January 2022 Figure 24: Synergistic Activities Share (by Company), January 2018-January 2022 Figure 25: Product Launches and Approvals (by Company), January 2018–January 2022 Figure 26: Share of Business Expansion (by Company), January 2018-January 2022 Figure 27: Market Share Analysis for Global Oncology Precision Medicine Market, $Million, 2020 Figure 28: Growth Share Analysis of Global Oncology Precision Medicine Market (by Application), 2021-2031 Figure 29: Growth Share Analysis of Global Oncology Precision Medicine Market (by Ecosystem), 2021-2031 Figure 30: FDA Guidelines for CDx Approval Figure 31: Year-Wise Analysis of Patents Related to Oncology Precision Medicine, January 2018-January 2022 Figure 32: Region-Wise Analysis of Patents Related to Oncology Precision Medicine, January 2018 - January 2022 Figure 33: Country-Wise Analysis of Patents Related to Oncology Precision Medicine, January 2018 - January 2022 Figure 34: Share of Global Oncology Precision Medicine Market (by Ecosystem), $Million, 2020 and 2031 Figure 35: Global Oncology Precision Medicine Market (Precision Therapeutics), $Million, 2020-2031 Figure 36: Global Oncology Precision Medicine Market (Clinical Trials), $Million, 2020-2031 Figure 37: Global Oncology Precision Medicine Market (Biomarker Testing), $Million, 2020-2031 Figure 38: Global Oncology Precision Medicine Market (Drug Discovery and Research), $Million, 2020-2031 Figure 39: Global Oncology Precision Medicine Market (Gene Therapy), $Million, 2020-2031 Figure 40: Global Oncology Precision Medicine Market (Cell Therapy), $Million, 2020-2031 Figure 41: Global Oncology Precision Medicine Market (Applied Sciences), $Million, 2020-2031 Figure 42: Global Oncology Precision Medicine Market (Genomics), $Million, 2020-2031 Figure 43: Global Oncology Precision Medicine Market (PCR), $Million, 2020-2031 Figure 44: Global Oncology Precision Medicine Market (Precision Medicine NGS), $Million, 2020-2031 Figure 45: Global Oncology Precision Medicine Market (Genome Editing), $Million, 2020-2031 Figure 46: Global Oncology Precision Medicine Market (Other Technologies) $Million, 2020-2031 Figure 47: Global Oncology Precision Medicine Market (Pharmacogenomics), $Million, 2020-2031 Figure 48: Global Oncology Precision Medicine Market (Other Applied Sciences), $Million, 2020-2031 Figure 49: Global Oncology Precision Medicine Market (Digital Health and Information Technology), $Million, 2020-2031 Figure 50: Global Oncology Precision Medicine Market (CDSS), $Million, 2020-2031 Figure 51: Global Oncology Precision Medicine Market (Big Data Analytics), $Million, 2020-2031 Figure 52: Global Oncology Precision Medicine Market (IT Infrastructure), $Million, 2020-2031 Figure 53: Global Oncology Precision Medicine Market (Genomics Informatics), $Million, 2020-2031 Figure 54: Global Oncology Precision Medicine Market (In-Silico Informatics), $Million, 2020-2031 Figure 55: Global Oncology Precision Medicine Market (Mobile Health), $Million, 2020-2031 Figure 56: Global Oncology Precision Medicine Market (Precision Diagnostics), $Million, 2020-2031 Figure 57: Global Oncology Precision Medicine Market (Molecular Diagnostics), $Million, 2020-2031 Figure 58: Global Oncology Precision Medicine Market (Medical Imaging), $Million, 2020-2031 Figure 59: Global Oncology Precision Medicine Market (by Application), $Million, 2020 and 2031 Figure 60: Global Oncology Precision Medicine Market (Solid Tumor), $Million, 2020-2031 Figure 61: Global Oncology Precision Medicine Market (Breast Cancer), $Million, 2020-2031 Figure 62: Global Oncology Precision Medicine Market (Lung Cancer), $Million, 2020-2031 Figure 63: Global Oncology Precision Medicine Market (Colorectal Cancer), $Million, 2020-2031 Figure 64: Global Oncology Precision Medicine Market (Prostate Cancer), $Million, 2020-2031 Figure 65: Global Oncology Precision Medicine Market (Cervical Cancer), $Million, 2020-2031 Figure 66: Global Oncology Precision Medicine Market (Other Cancer), $Million, 2020-2031 Figure 67: Global Oncology Precision Medicine Market (Hematological Malignancies), $Million, 2020-2031 Figure 68: Global Oncology Precision Medicine Market (Leukemia), $Million, 2020-2031 Figure 69: Global Oncology Precision Medicine Market (Lymphoma), $Million, 2020-2031 Figure 70: Global Oncology Precision Medicine Market (Myeloma), $Million, 2020-2031 Figure 71: Global Oncology Precision Medicine Market (Other Hematological Malignancies), $Million, 2020-2031 Figure 72: Global Oncology Precision Medicine Market (by Region), 2020-2031 Figure 73: Share of North America Oncology Precision Medicine Market (by Country), $Million, 2020 and 2031 Figure 74: North America: Market Dynamics Figure 75: North America Oncology Precision Medicine Market (by Application), $Million, 2020 and 2031 Figure 76: U.S. Oncology Precision Medicine Market, $Million, 2020-2031 Figure 77: Canada Oncology Precision Medicine Market, $Million, 2020-2031 Figure 78: Europe Oncology Precision Medicine Market (by Country), $Million, 2020 and 2031 Figure 79: Europe: Market Dynamics Figure 80: Europe Oncology Precision Medicine Market (by Application), $Million, 2020 and 2031 Figure 81: Germany Oncology Precision Medicine Market, $Million, 2020-2031 Figure 82: U.K. Oncology Precision Medicine Market, Million, 2020-2031 Figure 83: France Oncology Precision Medicine Market, $Million, 2020-2031 Figure 84: Italy Oncology Precision Medicine Market, $Million, 2020-2031 Figure 85: Spain Oncology Precision Medicine Market, $Million, 2020-2031 Figure 86: Rest-of-Europe Oncology Precision Medicine Market, $Million, 2020-2031 Figure 87: APAC: Market Dynamics Figure 88: Asia-Pacific Oncology Precision Medicine Market (by Country), $Million, 2020 and 2031 Figure 89: Asia-Pacific Oncology Precision Medicine Market (by Application), $Million, 2020 and 2031 Figure 90: China Oncology Precision Medicine Market, $Million, 2020-2031 Figure 91: India Oncology Precision Medicine Market, $Million, 2020-2031 Figure 92: Japan Oncology Precision Medicine Market, $Million, 2020-2031 Figure 93: Australia Oncology Precision Medicine Market, Million, 2020-2031 Figure 94: South Korea Oncology Precision Medicine Market, Million, 2020-2031 Figure 95: Rest-of-Asia-Pacific Oncology Precision Medicine Market, $Million, 2020-2031 Figure 96: LATAM: Market Dynamics Figure 97: Latin America Oncology Precision Medicine Market (by Country), $Million, 2020-2031 Figure 98: Latin America Oncology Precision Medicine Market (by Application), $Million, 2020 and 2031 Figure 99: Brazil Oncology Precision Medicine Market, $Million, 2020-2031 Figure 100: Mexico Oncology Precision Medicine Market, Million, 2020-2031 Figure 101: Rest-of-Latin America Oncology Precision Medicine Market, $Million, 2020-2031 Figure 102: Rest-of-the-World Oncology Precision Medicine Market, $Million, 2020-2031 Figure 103: Rest-of-the-World Oncology Precision Medicine Market (by Application), $Million, 2020 and 2031 Figure 104: Share of Key Company Profiled (22) Figure 105: Agilent Technologies, Inc.: Product Portfolio Figure 106: Agilent Technologies, Inc.: Overall Financials, $Million, 2019-2021 Figure 107: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 108: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021 Figure 109: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 110: Agilent Technologies, Inc.: SWOT Analysis Figure 111: Bio-Rad Laboratories, Inc.: Product Portfolio Figure 112: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2018-2020 Figure 113: Bio-Rad Laboratories, Inc.: Revenue (by Business Segment), $Million, 2018-2020 Figure 114: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2018-2020 Figure 115: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2018-2020 Figure 116: Bio-Rad Laboratories, Inc.: SWOT Analysis Figure 117: Illumina, Inc.: Product Portfolio Figure 118: Illumina, Inc.: Overall Financials, $Million, 2018-2020 Figure 119: Illumina, Inc.: Revenue (by Segment), $Million, 2018-2020 Figure 120: Illumina, Inc.: Revenue (by Region), $Million, 2018-2020 Figure 121: Illumina, Inc.: R&D Expenditure, $Million, 2018-2020 Figure 122: Illumina, Inc.: SWOT Analysis Figure 123: Pacific Biosciences of California, Inc.: Product Portfolio Figure 124: Pacific Biosciences of California, Inc.: Overall Financials, $Million, 2018-2020 Figure 125: Pacific Biosciences of California, Inc.: Revenue (by Segment), $Million, 2018-2020 Figure 126: Pacific Biosciences of California, Inc.: Revenue (by Region), $Million, 2018-2020 Figure 127: Pacific Biosciences of California, Inc.: R&D Expenditure, $Million, 2018-2020 Figure 128: Pacific Biosciences of California, Inc.: SWOT Analysis Figure 129: PerkinElmer Inc.: Product Portfolio Figure 130: PerkinElmer Inc.: Overall Financials, $Million, 2018-2020 Figure 131: PerkinElmer Inc.: Revenue (by Segment), $Million, 2018-2020 Figure 132: PerkinElmer Inc: Revenue (by Region), $Million, 2018-2020 Figure 133: PerkinElmer Inc. R&D Expenditure, $Million, 2018-2020 Figure 134: PerkinElmer Inc.: SWOT Analysis Figure 135: QIAGEN: Portfolio Figure 136: QIAGEN: Overall Financials, $Million, 2018-2020 Figure 137: QIAGEN: Revenue (by Segment), $Million, 2018-2020 Figure 138: QIAGEN: Revenue (by Region), $Million, 2018-2020 Figure 139: QIAGEN: R&D Expenditure, $Million, 2018-2020 Figure 140: QIAGEN: SWOT Analysis Figure 141: Thermo Fisher Scientific, Inc.: Product Portfolio Figure 142: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2018-2020 Figure 143: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), $Million, 2018-2020 Figure 144: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2018-2020 Figure 145: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2018-2020 Figure 146: Thermo Fisher Scientific Inc.: SWOT Analysis Figure 147: BGI Product Portfolio Figure 148: BGI Group: SWOT Analysis Figure 149: ASURAGEN, INC.: Overall Product Offerings Figure 150: ASURAGEN,INC.: SWOT Analysis Figure 151: Almac Group Ltd.: Overall Product Offerings Figure 152: Almac Group Ltd.: SWOT Analysis Figure 153: MDxHealth: Service Portfolio Figure 154: MDxHealth: Overall Financials, $Million, 2018-2020 Figure 155: MDxHealth: Revenue (by Segment), $Million, 2018-2020 Figure 156: MDxHealth: Revenue (by Region), $Million, 2018-2020 Figure 157: MDxHealth: R&D Expenditure, $Million, 2018-2020 Figure 158: MdxHealth: SWOT Analysis Figure 159: Abbott Laboratories: Overall Product Offerings Figure 160: Abbott Laboratories: Overall Financials, $Million, 2018-2020 Figure 161: Abbott Laboratories: Net Revenue (by Business Segment), $Million, 2018-2020 Figure 162: Abbott Laboratories: Net Revenue (by Region), $Million, 2018-2020 Figure 163: Abbott Laboratories: R&D Expenditure, $Million, 2018-2020 Figure 164: Abbott Laboratories: SWOT Analysis Figure 165: F. Hoffmann-La Roche Ltd: Product Portfolio Figure 166: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021 Figure 167: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2019-2021 Figure 168: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Million, 2019-2021 Figure 169: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021 Figure 170: F. Hoffmann-La Roche Ltd: SWOT Analysis Figure 171: Gilead Sciences, Inc.: Overall Product Portfolio Figure 172: Gilead Sciences, Inc.: Overall Financials, $Million, 2018-2020 Figure 173: Gilead Sciences, Inc.: R&D Expenditure, $Million, 2018-2020 Figure 174: Gilead Sciences, Inc.: SWOT Analysis Figure 175: Myriad Genetics, Inc.: Product Portfolio Figure 176: Myriad Genetics, Inc.: Overall Financials, $Million, 2018-2020 Figure 177: Myriad Genetics, Inc.: Revenue (by Business Segment), $Million, 2018-2020 Figure 178: Myriad Genetics, Inc.: R&D Expenditure, $Million, 2018-2020 Figure 179: Myriad Genetics, Inc.: SWOT Analysis Figure 180: OPKO Health, Inc.: Overall Product Portfolio Figure 181: OPKO Health, Inc.: Overall Financials, $Million, 2018-2020 Figure 182: OPKO Health, Inc: Net Revenue (by Business Segment), $Million, 2018-2020 Figure 183: OPKO Health, Inc.: Net Revenue (by Region), $Million, 2018-2020 Figure 184: OPKO Health, Inc.: R&D Expenditure, $Million, 2018-2020 Figure 185: OPKO Health, Inc.: SWOT Analysis Figure 186: Quest Diagnostics Incorporated: Overall Product Offerings Figure 187: Quest Diagnostics Incorporated: Overall Financials, $Million, 2018-2020 Figure 188: Quest Diagnostics Incorporated: Revenue (by Business Segment), $Million, 2018-2020 Figure 189: Quest Diagnostics Incorporated: SWOT Analysis Figure 190: Novartis AG: Overall Product Portfolio Figure 191: Novartis AG: Overall Financials, $Million, 2019-2021 Figure 192: Novartis AG: Revenue (by Business Segment), $Million, 2019-2021 Figure 193: Novartis AG: SWOT Analysis List of Tables Table 1: Estimated New Cancer Cases (by Type) in U.S., 2022 Table 2: Potential Usage of Biomarkers in Cancer Diagnostics Table 3: List of Initiatives for Precision Oncology Research in 2018 Table 4: List of Few FDA-Approved Pharmacogenomics Biomarkers in Drug Labeling Table 5: Estimated New Cancer Cases and Deaths in the U.S., 2020 Table 6: Key Competitors of North America Oncology Precision Medicine (by Ecosystem), 2020 Table 7: Key Competitors of Europe Oncology Precision Medicine (by Ecosystem), 2020 Table 8: Key Competitors of Asia-Pacific Oncology Precision Medicine (by Ecosystem), 2020 Table 9: Key Competitors of Latin America Oncology Precision Medicine (by Ecosystem), 2020 Table 10: Key Competitors of Rest-of-the-World Oncology Precision Medicine (by Ecosystem), 2020 Table 11: BIS Insight for Prelude Therapeutics Table 12: BIS Insight for AceTech Table 13: BIS Insight for Flatiron Table 14: BIS Insight for Biosplice Therapeutics, Inc.